Krell-Roesch, Janina
Vassilaki, Maria
Mielke, Michelle M.
Kremers, Walter K.
Lowe, Val J.
Vemuri, Prashanthi
Machulda, Mary M.
Christianson, Teresa J.
Syrjanen, Jeremy A.
Stokin, Gorazd B.
Butler, Lesley M.
Traber, Martin
Jack, Clifford R. Jr.
Knopman, David S.
Roberts, Rosebud O.
Petersen, Ronald C.
Geda, Yonas E.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01 AG057708, R01 AG041851, R01 AG011378, R01 AG041851, K01 AG028573, U01 AG006786, P50 AG016574)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K01 MH068351)
Robert Wood Johnson Foundation
Article History
Received: 11 February 2019
Accepted: 16 February 2019
First Online: 28 March 2019
Conflict of interest
: J.K.-R. receives funding from NIH and Roche. M.V. receives research funding from NIH, Roche, and Biogen. M.M.M. has consulted for Eli Lilly and Lysosomal Therapeutics, Inc. and receives unrestricted research grants from Biogen and Lundbeck, and research funding from the NIH/NIA and Department of Defense. W.K.K. receives research funding from Department of Defense, NIH, Astra Zeneca, Biogen, and Roche. V.J.L. serves on scientific advisory boards for Bayer Schering Pharma, Piramal Life Sciences, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). P.V. receives NIH funding. M.M.M. receives funding from NIH. L.M.B. and M.T. are full-time employees of, and own shares at, F. Hoffmann-La Roche Ltd. C.R.J. serves on scientific advisory board for Eli Lilly and IDSMB for Roche. But he receives no compensation from any commercial entity. He receives research support from the NIH/NIA and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Foundation. D.S.K. serves on a Data Safety Monitoring Board for the DIAN study. He is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the Alzheimer’s Treatment and Research Institute at USC and receives research support from the NIH. R.O.R. receives research funding from the NIH/NIA, Biogen, and Roche. R.C.P. is a consultant for Roche, Biogen, Merck, Eli Lilly, and Genentech. He receives publishing royalties from <i>Mild Cognitive Impairment</i> (Oxford University Press, 2003) and research support from the NIH. Y.E.G. receives funding from NIH and Roche and serves on Lundbeck Advisory Board. The other authors declare that they have no conflict of interest.